A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)
NCT04777409 on ClinicalTrials.gov · last registry update 2026-06-26
An unusually large phase 3: 1,840 participants, more than double the 424 typical for the stage. The sponsor logged completion for 15 September 2025. Primary outcome, as filed: Change in the Clinical Dementia Rating - Sum of Boxes (CDR-SB) score. semaglutide is approved in the US, but not for neurodegenerative — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P3
- Drug
- semaglutideWegovy, Ozempic, Rybelsus
- Sponsor
- Novo Nordisk A/S
- Sponsor type
- Industry
- Enrollment
- 1,840
- Started
- 2021-05-18
- Primary completion
- 2025-09-15 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in the Clinical Dementia Rating - Sum of Boxes (CDR-SB) score
Conditions studied
Early Alzheimer´s Disease
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.